Readoutin 45d
Xenon Pharmaceuticals Inc. — Azetukalner
Phase 3 primary completion: An Open-Label Study of Azetukalner in Major Depressive Disorder.
- Date
- Jan 2027
- Type
- Readout
- Indication
- Major Depressive Disorder
Readoutin 45d
Phase 3 primary completion: An Open-Label Study of Azetukalner in Major Depressive Disorder.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.